{
    "symbol": "XNCR",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-08 03:09:06",
    "content": " Now looking at our partnerships for the XmAb bispecific Fc demand in our T-cell engager toolkit, last quarter, we highlighted encouraging early clinical data from Amgen\u2019s AMG 509 program in prostate cancer, which, in addition to being an XmAb bispecific, uses the XmAb 2+1 multi-valent format for T cell engagement. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open."
}